Company Active LTD

Company profile

LGC Limited

LGC Group - LGC Group

LGC Group is a global leader in the life sciences sector; our scientific tools and solutions are essential to our customers goals.

CRN
02991879
Founded
1994
Age
31

Overview

Legal name
LGC LIMITED
Region
South East England
Registered address
THE PRIESTLEY CENTRE 10 PRIESTLEY ROAD
SURREY RESEARCH PARK
GUILDFORD
ENGLAND
GU2 7XY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

15 levels 1 ultimate controller Controls 9
1
Company Active LTD
LGC Limited
CRN 02991879
2
Direct controller Active LTD
LGC (Holdings) Limited
CRN 03141667
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active LTD
Teddington 2 Limited
CRN 07110936
8
Intermediate controller Active LTD
9
Intermediate controller Active LTD
Teddington 3 Limited
CRN 09903564
10
Intermediate controller Active LTD
Elwy 3 Limited
CRN 09905519
11
Intermediate controller Active LTD
Elwy 2 Limited
CRN 09905091
12
Intermediate controller Active LTD
Loire UK Bidco Limited
CRN 12315743
13
Intermediate controller Active LTD
14
Intermediate controller Active LTD
15
Intermediate controller Active LTD
16
Ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

8 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

02 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

18 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

18 Nov
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0MzcwNzI5NWFkaXF6a2N4

Published 18 Nov 2024 12:20

05 Nov
2024

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzQ0MjAxMTA1OWFkaXF6a2N4 | Paper/PDF filed

Published 10 Nov 2024 06:41

30 Sep
2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQzNzcxNDg5OWFkaXF6a2N4

Published 30 Sep 2024 10:53

18 Nov
1994

Incorporated

Inception

Company registered at Companies House

Public funding

61 awards
First funded
2005
Funded years
2005, 2006, 2008, 2010, 2011, 2012, 2013, 2014, 2016, 2017, 2018, 2019, 2020, 2022, 2023, 2024, 2026
Age at first award
10 years

Projects

2026 Grant for R&D

Enabling reproducible and scalable AAV production through advanced metabolomic analysis of HEK293 suspension cells

1 Apr 2026 to 30 Jun 2026

Awarded
£34,718
Total cost £34,718

This project will pioneer a new approach to making viral vectors --- the essential building blocks for many advanced therapies --- by combining precision small-scale manufacturing with world-class molecular measurement. It brings together BiologIC Technologies, developer of the Qudos personal biomanufacturing system, and the National Measurement Laborator...

2026 Grant for R&D

A4I - Critical enablers

1 Feb 2026 to 31 Jul 2026

Awarded
£59,549
Total cost £59,549

Agroceutical Products Ltd is developing a reliable UK supply of **galanthamine**, a licensed medicine used to treat symptoms of Alzheimer's disease and found naturally in daffodils. Our main research project, **GalanCEAmine**, uses controlled-environment farming and a new extraction process to increase the amount of this valuable molecule we can obtain fr...

2026 Grant for R&D

SMRT-FIT – characterisation of SupraMolecular RNA Therapeutic formulations to accelerate regulatory path to First-In-human clinical Trials

1 Feb 2026 to 31 Jul 2026

Awarded
£59,301
Total cost £59,301

This A4I project will support Innovate-UK funding for development of a novel "**S**upra**M**olecular" **R**NA **T**herapeutic (**SMRT**) delivery system and flexible, scalable RNA-manufacturing process for the sustainable manufacture of biologic drugs. Combined, the material and process will reduce considerably the material-use and energy-costs compared t...

2024 Collaborative R&D

Functionalised Graphene Electrode Biosensor

1 Sep 2024 to 30 Nov 2024

Awarded
£0
Total cost £19,000

ProMake sets to represent a ground-breaking initiative aimed at revolutionising the landscape of diagnostic technologies through the development and validation of an innovative biosensor technology. This initiative is set to transform the way pathogens, including viruses and bacteria, are detected, making strides towards offering a rapid, sensitive, and c...

2024 Collaborative R&D

Removal of colouration from product

1 Sep 2024 to 28 Feb 2025

Awarded
£0
Total cost £43,500

**Aqdot**, a young **UK-based** Chemtech company, has completed relevant regulatory approvals and is now accelerating scaling of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests". Cucurbit\[n\]urils have potential...

2024 EU-Funded Lead participant

Standardised measurements of surface functionalities on nanoparticles

1 Jul 2024 to 30 Jun 2027

Awarded
£39,171
Total cost £39,171

Engineered nanoparticles have great application potential in fields such as medicine, sensing, catalysis, energy storage, and opto-electronics. The utility and performance of engineered nanoparticles is largely determined by their surface chemistry. However, documented standards to measure such surface chemistry and functionality do not currently exist. S...

2024 Collaborative R&D

Improvement of microbiome sample processing and analysis using novel testing standards

1 Jun 2024 to 31 Aug 2024

Awarded
£0
Total cost £25,000

Salient Labs Ltd is a UK-based biomedical diagnostics SME with a focus on microbiome analysis. Microbiomes are integral to an individual's health, and microbiome composition can be used to diagnose or predict the risk of disease. The oral microbiome has been implicated in both dental disease and systemic diseases such as diabetes and cancer. Disease diagn...

2024 Collaborative R&D

Understand and eliminate batch-to-batch variation in solubility of cucurbit[n]uril

1 May 2024 to 31 Oct 2024

Awarded
£0
Total cost £45,000

**Aqdot**, a young **UK-based company**, has completed all relevant regulatory and environmental hurdles and is now accelerating production and commercialisation of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests...

2024 Collaborative R&D

Analysis and quality control of novel mixed cell population for therapeutic development

1 Jan 2024 to 30 Jun 2024

Awarded
£0
Total cost £60,300

This project will focus on developing a critical quality control (QC) method that will allow manufacturers to test and ensure the quality of an immune therapy (called BioThymus). The BioThymus therapy is designed to treat a life-threatening disease in infants. Children born without a thymus gland (called complete DiGeorge Syndrome or cDGS) have a poorly f...

2024 Collaborative R&D

Indoor air quality measurements of formaldehyde using low cost sensors

1 Jan 2024 to 31 Mar 2024

Awarded
£0
Total cost £28,000

Formaldehyde is a significant health risk, and International Agency for Research on Cancer (IARC) classifies formaldehyde as a human carcinogen. There are stringent formaldehyde exposure guidelines that exist for indoor air (80 ppb WHO) that can be even lower at the national level (e.g., France 8 ppb by 2023). People are exposed to formaldehyde from a var...

2024 Collaborative R&D

Mutated human oncogene recombinant nucleosomes as reference materials for liquid biopsy

1 Jan 2024 to 30 Jun 2024

Awarded
£0
Total cost £68,000

Circulating tumour DNA (ctDNA) sequencing of plasma samples is becoming commonplace in clinical oncology practice and holds the promise to revolutionise cancer disease diagnosis and management. This promise is impeded by poor standardisation of ctDNA sequencing workflows, particularly in the pre-analytical phase. Limited control materials are currently av...

2024 Collaborative R&D

RADWIPES - Performance and Cleaning Efficacy

1 Jan 2024 to 31 Mar 2024

Awarded
£0
Total cost £12,400

RADWIPES is the brand name of a cleaning product developed by MDCO Ltd. RADWIPES have been developed specifically for radiation decontamination activities associated with the decommissioning cleanup operations of legacy buildings on UK nuclear licensed sites, many of which, fall under the umbrella of the N.D.A. - Nuclear Decommissioning Authority. The ini...

Product types

Collaborative R&D EU-Funded Grant for R&D Knowledge Transfer Partnership